ClinicalTrials.gg
RecruitingNCT05032326OTBB3-FUUpdated Apr 30, 2024

Long-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial

A Phase 3 interventional study of Follow-up study of the treated cohort and Follow-up study of the untreated cohort in Prader-Willi Syndrome, sponsored by University Hospital, Toulouse. Recruiting at 12 sites in France. Open to participants aged 12 Months to 36 Months. Per ClinicalTrials.gov, last updated 2024-04-30.

Sponsored by University Hospital, Toulouse · Phase 3, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
12 Months to 36 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Prader-Willi Syndrome by University Hospital, Toulouse — 6 open to participants now, 6 under way, 1 of them phase 3. Prader-Willi Syndrome · University Hospital, Toulouse.

Planned enrollment
3rd of 14
80 · median 37
Started
2021
with 1 other
Phase 3
2 of 17
1 open now
Registered
13th of 17
by date

Among the 17 studies in Prader-Willi Syndrome by University Hospital, Toulouse, this one is the 3rd largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2021, is one of 2 in phase 3, and was the 13th registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

6 of the 17 studies in Prader-Willi Syndrome by University Hospital, Toulouse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 12 Months to 36 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Prader-Willi Syndrome by University Hospital, Toulouse, or all of them as a file.
02

Study summary

This study is a prospective, multicentre, interventional cohort study in children with Prader-Willi Syndrome (PWS) over 4 years (no treatment administered). The duration of the preceding OTTB3 study is 26 weeks. An untreated cohort of children with PWS will be included at an age of 2 years and followed up until an age of 4 years.

Regarding the untreated cohort, children with PWS born in France and too old to be recruited in OTBB3 trial, principally those who were born within one year before the start of OTBB3 trial, will be offered to participate in this study. Infants born later who couldn't be included in OTBB3 study will be also offered to participate.

03

Conditions studied

  • Prader-Willi Syndrome

Browse trials for

Keywords

  • Prader-Willi syndrome
  • Oxytocin
04

Who can participate

Ages eligible
12 Months to 36 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female child with a genetically confirmed diagnosis of PWS (patients can be enrolled if the genetic subtype is not available at inclusion, but the genetic subtype needs to be confirmed during the study);
  2. The parents (or legal representative) must have signed the consent form;
  3. Treated cohort: the child participated in the OTBB3 study and is aged 16±4 months at inclusion,
  4. Untreated cohort: the child has never received OT, is aged 30±6 months at inclusion (in order to maximise the number of children in the untreated cohort) and is followed in France.

Exclusion criteria

Exclusion Criteria:

  1. Administrative problems:

    1. Inability for the parents (or legal representative) to understand/fulfil study requirements;
    2. No coverage by a social security regime;
  2. Refusal of parents (or legal representative) to sign the consent form;
05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Other
    OXYTOCIN (OT) Treated cohort

    babies treated with Oxytocin during the OTBB3 study

    Drug: Follow-up study of the treated cohort

  • Other
    Untreated cohort

    babies not included in the OTBB3 study and therefore never treated with Oxytocin

    Other: Follow-up study of the untreated cohort

Interventions

  • DrugFollow-up study of the treated cohort

    follow-up study of the patients in the treated cohort: that have been included in the otbb3 study

  • OtherFollow-up study of the untreated cohort

    follow-up study of the patients in the untreated cohort: that have NOT been included in the otbb3 study

06

What researchers measure

Primary outcomes

  1. Confirmation of the long term safety profile (1)

    The number of patients with adverse events (AEs)

    Time frame: 4 years

  2. Confirmation of the long term safety profile (2)

    The percentage of patients with adverse events (AEs)

    Time frame: 4 years

  3. Confirmation of the long term safety profile (3)

    Assessment in the treated cohort of the occurrence of the main comorbidities in Prader Willi Syndrome

    Time frame: 4 years

  4. Confirmation of the long term safety profile (4)

    Assessment in the treated cohort of: The occurrence of medications, surgery and rehabilitations by collecting type, age (years) at start and stop, dosing or frequency

    Time frame: 4 years

Secondary outcomes

  1. Complete the safety assessment by the description of the development of the child (1.1)

    Assessment in the treated cohort of: weight (kilograms)

    Time frame: 4 years

  2. Complete the safety assessment by the description of the development of the child (1.2)

    Assessment in the treated cohort of: height (meters)

    Time frame: 4 years

  3. Complete the safety assessment by the description of the development of the child (1.3)

    Assessment in the treated cohort of: BMI (kg/m\^2)

    Time frame: 4 years

  4. Complete the safety assessment by the description of the development of the child (2.1)

    Assessment in the treated cohort of Child development: age at which sitting has been reached

    Time frame: 4 years

  5. Complete the safety assessment by the description of the development of the child (2.2)

    Assessment in the treated cohort of Child development: age at which crawling has been reached

    Time frame: 4 years

  6. Complete the safety assessment by the description of the development of the child (2.3)

    Assessment in the treated cohort of Child development: age at which walking has been reached

    Time frame: 4 years

  7. Complete the safety assessment by the description of the development of the child (2.4)

    Assessment in the treated cohort of Child development: age at which running has been reached

    Time frame: 4 years

  8. Complete the safety assessment by the description of the severity of the disease

    Severity of the disease for: Eating disorders by using Hyperphagia Questionnaire for Clinical Trials (HQCT);

    Time frame: 4 years

  9. Complete the safety assessment by the description of the severity of the disease (2)

    Severity of the disease for: Psychiatric disorders by using the Child Behaviour Checklist (CBCL);

    Time frame: 4 years

  10. Assessment of endocrine disorders by IGF1

    Analysis of plasma Insulin-like growth factor 1 (IGF1, ng/mL)

    Time frame: 4 years

  11. Assessment of endocrine disorders by TSH

    Analysis of plasma thyroid stimulating hormone (TSH, µUI/mL)

    Time frame: 4 years

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2021 (actual). Primary completion is estimated for Apr 2025, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2021
First posted
Sep 2, 2021
StartActual
Sep 7, 2021
Primary completionEst.
Apr 1, 2025
CompletionEst.
Apr 1, 2025
Last update
Apr 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05032326
Responsible party
Sponsor
First posted
Sep 2, 2021
Start date
Sep 7, 2021
Primary completion
Apr 1, 2025 (estimated)
Completion
Apr 1, 2025 (estimated)
Last update
Apr 30, 2024

Study contacts

Maithé TAUBER, MD
Contact
tauber.mt@chu-toulouse.fr
534 55 85 51 ext. +33
Julie CORTADELLAS
Contact
cortadellas.j@chu-toulouse.fr
534 55 85 51 ext. +33
Maithé TAUBER, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion